• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COPD 加重期肺部微生物组动态变化。

Lung microbiome dynamics in COPD exacerbations.

机构信息

Computational Biology, Target Sciences, GSK R&D, Collegeville, PA, USA These authors contributed equally.

Respiratory Medicine Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK These authors contributed equally.

出版信息

Eur Respir J. 2016 Apr;47(4):1082-92. doi: 10.1183/13993003.01406-2015. Epub 2016 Feb 25.

DOI:10.1183/13993003.01406-2015
PMID:26917613
Abstract

Increasing evidence suggests that the lung microbiome plays an important role in chronic obstructive pulmonary disease (COPD) severity. However, the dynamics of the lung microbiome during COPD exacerbations and its potential role in disease aetiology remain poorly understood.We completed a longitudinal 16S ribosomal RNA survey of the lung microbiome on 476 sputum samples collected from 87 subjects with COPD at four visits defined as stable state, exacerbation, 2 weeks post-therapy and 6 weeks recovery.Our analysis revealed a dynamic lung microbiota where changes appeared to be associated with exacerbation events and indicative of specific exacerbation phenotypes. Antibiotic and steroid treatments appear to have differential effects on the lung microbiome. We depict a microbial interaction network for the lung microbiome and suggest that perturbation of a few bacterial operational taxonomic units, in particular Haemophilus spp., could greatly impact the overall microbial community structure. Furthermore, several serum and sputum biomarkers, in particular sputum interleukin-8, appear to be highly correlated with the structure and diversity of the microbiome.Our study furthers the understanding of lung microbiome dynamics in COPD patients and highlights its potential as a biomarker, and possibly a target, for future respiratory therapeutics.

摘要

越来越多的证据表明,肺部微生物组在慢性阻塞性肺疾病(COPD)的严重程度中起着重要作用。然而,COPD 恶化期间肺部微生物组的动态变化及其在疾病发病机制中的潜在作用仍知之甚少。我们对 87 名 COPD 患者的 476 份痰样本进行了为期 16S 核糖体 RNA 的纵向肺部微生物组调查,这些样本在四次就诊时采集,分别定义为稳定状态、恶化、治疗后 2 周和恢复后 6 周。我们的分析揭示了一个动态的肺部微生物群,其中变化似乎与恶化事件有关,并提示了特定的恶化表型。抗生素和类固醇治疗似乎对肺部微生物组有不同的影响。我们描绘了肺部微生物组的微生物相互作用网络,并提出少数细菌操作分类单元(特别是嗜血杆菌属)的扰动可能会极大地影响整体微生物群落结构。此外,一些血清和痰生物标志物,特别是痰白细胞介素-8,似乎与微生物组的结构和多样性高度相关。我们的研究进一步了解了 COPD 患者肺部微生物组的动态变化,并强调了其作为未来呼吸治疗的生物标志物和潜在靶点的潜力。

相似文献

1
Lung microbiome dynamics in COPD exacerbations.COPD 加重期肺部微生物组动态变化。
Eur Respir J. 2016 Apr;47(4):1082-92. doi: 10.1183/13993003.01406-2015. Epub 2016 Feb 25.
2
Dynamic changes of gut and lung microorganisms during chronic obstructive pulmonary disease exacerbations.慢性阻塞性肺疾病恶化过程中肠道和肺部微生物的动态变化。
Kaohsiung J Med Sci. 2020 Feb;36(2):107-113. doi: 10.1002/kjm2.12147. Epub 2019 Nov 29.
3
Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations.AERIS 研究中的肺部微生物组纵向分析表明细菌和嗜酸性 COPD 加重具有可重复性。
Thorax. 2018 May;73(5):422-430. doi: 10.1136/thoraxjnl-2017-210408. Epub 2018 Jan 31.
4
The Sputum Microbiome in Chronic Obstructive Pulmonary Disease Exacerbations.慢性阻塞性肺疾病急性加重期的痰液微生物组
Ann Am Thorac Soc. 2015 Nov;12 Suppl 2(Suppl 2):S176-80. doi: 10.1513/AnnalsATS.201506-319AW.
5
Sputum Microbiome, Potentially Pathogenic Organisms, and Clinical Outcomes in Japanese Patients with COPD and Moderate Airflow Limitation: The Prospective AERIS-J Study.日本慢性阻塞性肺疾病(COPD)合并中度气流受限患者的痰液微生物组、潜在致病生物与临床结局:前瞻性AERIS-J研究
Int J Chron Obstruct Pulmon Dis. 2025 May 14;20:1477-1492. doi: 10.2147/COPD.S481406. eCollection 2025.
6
Short term dynamics of the sputum microbiome among COPD patients.COPD 患者痰液微生物组的短期动态变化。
PLoS One. 2018 Mar 8;13(3):e0191499. doi: 10.1371/journal.pone.0191499. eCollection 2018.
7
Airway host-microbiome interactions in chronic obstructive pulmonary disease.慢性阻塞性肺疾病中的气道宿主-微生物组相互作用。
Respir Res. 2019 Jun 6;20(1):113. doi: 10.1186/s12931-019-1085-z.
8
Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis.慢性阻塞性肺疾病临床稳定期和加重期的炎症表型相关气道微生物组:一项多队列纵向分析。
Am J Respir Crit Care Med. 2021 Jun 15;203(12):1488-1502. doi: 10.1164/rccm.202009-3448OC.
9
Microbial burden and viral exacerbations in a longitudinal multicenter COPD cohort.纵向多中心 COPD 队列中的微生物负担和病毒加重。
Respir Res. 2020 Mar 30;21(1):77. doi: 10.1186/s12931-020-01340-0.
10
Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease.慢性阻塞性肺疾病急性加重期的气道微生物群动态变化
J Clin Microbiol. 2014 Aug;52(8):2813-23. doi: 10.1128/JCM.00035-14. Epub 2014 May 21.

引用本文的文献

1
Exploring the metabolomics and metagenomics of chronic obstructive pulmonary disease (COPD) and lung cancer: unraveling the complex interplay.探索慢性阻塞性肺疾病(COPD)和肺癌的代谢组学与宏基因组学:揭示复杂的相互作用。
J Thorac Dis. 2025 Jul 31;17(7):5268-5281. doi: 10.21037/jtd-2025-278. Epub 2025 Jul 29.
2
Distribution of two CD4FOXP3 T cell subpopulations reflects disease phenotypes and prognosis in COPD.两种CD4FOXP3 T细胞亚群的分布反映慢性阻塞性肺疾病的疾病表型和预后。
Sci Rep. 2025 May 22;15(1):17721. doi: 10.1038/s41598-025-02935-7.
3
Sputum Microbiome, Potentially Pathogenic Organisms, and Clinical Outcomes in Japanese Patients with COPD and Moderate Airflow Limitation: The Prospective AERIS-J Study.
日本慢性阻塞性肺疾病(COPD)合并中度气流受限患者的痰液微生物组、潜在致病生物与临床结局:前瞻性AERIS-J研究
Int J Chron Obstruct Pulmon Dis. 2025 May 14;20:1477-1492. doi: 10.2147/COPD.S481406. eCollection 2025.
4
Characterizations of lung cancer microbiome and exploration of potential microbial risk factors for lung cancer.肺癌微生物组的特征及肺癌潜在微生物危险因素的探索。
Sci Rep. 2025 May 5;15(1):15683. doi: 10.1038/s41598-025-98424-y.
5
Analysis of the bronchoalveolar lavage fluid microbial flora in COPD patients at different lung function during acute exacerbation.慢性阻塞性肺疾病(COPD)患者急性加重期不同肺功能状态下支气管肺泡灌洗液微生物菌群分析
Sci Rep. 2025 Apr 16;15(1):13179. doi: 10.1038/s41598-025-96746-5.
6
The impact of environmental factors on respiratory tract microbiome and respiratory system diseases.环境因素对呼吸道微生物群和呼吸系统疾病的影响。
Eur J Med Res. 2025 Apr 4;30(1):236. doi: 10.1186/s40001-025-02517-3.
7
Refining the Concept of Disease Stability in Chronic Obstructive Pulmonary Disease: Bridging Complexity and Clinical Practice.完善慢性阻塞性肺疾病中疾病稳定性的概念:弥合复杂性与临床实践之间的差距
Am J Respir Crit Care Med. 2025 Jul;211(7):1307-1308. doi: 10.1164/rccm.202501-0084LE.
8
Differences in sputum microbiota based on cure status of patients with nontuberculous mycobacterial pulmonary disease.非结核分枝杆菌肺病患者痰液微生物群基于治愈状态的差异。
Korean J Intern Med. 2025 May;40(3):449-457. doi: 10.3904/kjim.2024.209. Epub 2025 Mar 25.
9
Burn inhalation injury and intubation with dexamethasone-eluting endotracheal tubes modulate local microbiome and alter airway inflammation.烧伤吸入性损伤及使用地塞米松洗脱气管导管插管可调节局部微生物群并改变气道炎症。
Front Bioeng Biotechnol. 2025 Feb 26;13:1524013. doi: 10.3389/fbioe.2025.1524013. eCollection 2025.
10
Keystone bacteria dynamics in chronic obstructive pulmonary disease (COPD): Towards differential diagnosis and probiotic candidates.慢性阻塞性肺疾病(COPD)中的关键细菌动态:迈向鉴别诊断和益生菌候选物
Heliyon. 2025 Feb 14;11(4):e42719. doi: 10.1016/j.heliyon.2025.e42719. eCollection 2025 Feb 28.